Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 14/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349129 | 0.93 | HSD11B1 (0.55) | HRH3NPY5RSIGMAR1HSD11B1CYP2D6 | |
| SCHEMBL30476276 | 0.87 | HSD11B1 (0.46) | HRH3NPY5RSIGMAR1HSD11B1CYP2D6 | |
| SCHEMBL30508369 | 0.85 | AVPR1A (0.48) | HRH3NPY5R | |
| SCHEMBL20955151 | 0.85 | NR1H2 (0.49) | HRH3NPY5R | |
| SCHEMBL17586448 | 0.85 | ALK (0.43) | HRH3NPY5R | |
| SCHEMBL11840173 | 0.84 | HRH3 (0.55) | HRH3NPY5RSIGMAR1HSD11B1CYP2D6 | |
| SCHEMBL2103144 | 0.82 | AVPR1A (0.50) | — | |
| SCHEMBL1223123 | 0.82 | STS (0.46) | NPY5RHSD11B1CYP2D6 | |
| SCHEMBL6079968 | 0.82 | PDK2 (0.49) | NPY5RHSD11B1CYP2D6 | |
| SCHEMBL4505432 | 0.82 | NPC1L1 (0.48) | HSD11B1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563764-B1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
| WO-2011137024-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, PEPD | HRH3 4638/4885NPY5R 1864/4885SIGMAR1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.